Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 20;15(10):1292.
doi: 10.3390/ph15101292.

[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

Ute Hennrich  1 , Matthias Eder  2   3
Affiliations
Review

[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

Ute Hennrich et al. Pharmaceuticals (Basel). .

Abstract

In March 2022, [177Lu]Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the treatment of prostate cancer patients. Until now, the approval has been limited to patients with PSMA-positive metastatic castration-resistant prostate cancer who have previously received other therapy options (such as inhibition of the androgen receptor pathway and taxane-based chemotherapy). [177Lu]Lu-PSMA-617, which combines a PSMA-specific peptidomimetic with a therapeutical radionuclide, is used in a radioligand therapy that selectively delivers ionizing radiation to tumor cells, causing their death, while sparing the surrounding healthy tissue. In numerous clinical trials, the efficacy of [177Lu]Lu-PSMA-617 was demonstrated.

Keywords: PSMA; PluvictoTM; [177Lu]Lu-PSMA-617; prostate cancer; radioligand therapy (RLT); theranostics.

PubMed Disclaimer

Conflict of interest statement

PSMA-617 is the subject of a patent, in which M.E. is an inventor. M.E. holds further patent rights on other PSMA inhibitors. There are no other conflicts of interest to report that are relevant to this article.

Figures

Figure 1
Figure 1
Development of PSMA-617.
Figure 2
Figure 2
Theranostic concept.
Figure 3
Figure 3
Chemical structure of [177Lu]Lu-PSMA-617.
See this image and copyright information in PMC

References

    1. Sartor O., de Bono J., Chi K.N., Fizazi K., Herrmann K., Rahbar K., Tagawa S.T., Nordquist L.T., Vaishampayan N., El-Haddad G., et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2021;385:1091–1103. doi: 10.1056/NEJMoa2107322. - DOI - PMC - PubMed
    1. Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer. Res. 1987;7:927–935. - PubMed
    1. Label for ProstaScint® Kit. [(accessed on 5 August 2022)]; Available online: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview....
    1. Hennrich U., Eder M. [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals. 2021;14:713. doi: 10.3390/ph14080713. - DOI - PMC - PubMed
    1. Pomper M.G., Musachio J.L., Zhang J., Scheffel U., Zhou Y., Hilton J., Maini A., Dannals R.F., Wong D.F., Kozikowski A.P. 11C-MCG: Synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase) Mol. Imaging. 2002;1:96–101. doi: 10.1162/153535002320162750. - DOI - PubMed

LinkOut - more resources